Stock LPTX LEAP THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Real-time Estimate Cboe BZX
Other stock markets
 19:15:51 06/05/2024 BST 		5-day change 1st Jan Change
3.19 USD 0.00% Intraday chart for Leap Therapeutics, Inc. +4.23% -22.80%
04-10 Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP CI
03-19 Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Top Premarket Decliners
Top Premarket Decliners
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients
Leap Therapeutics to Effect 10-for-1 Reverse Stock Split
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Leap Therapeutics Completes Enrollment of Part A of Phase 2 Study of Potential Colorectal Cancer Combination Therapy
Leap Therapeutics, Inc. Announces Completion of Enrollment in Part A of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients
Leap Therapeutics, Inc. Announces the Promotion of Jason Baum to Chief Scientific Officer, Effective April 1, 2023
Leap Therapeutics, Inc. Provides Update on Beigene Option Agreement for DKN-01
Tesla's China sales slow as price-cut boost wanes
Leap Therapeutics Acquires Flame Biosciences in All-Stock Deal
Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LPTX Stock
  4. News Leap Therapeutics, Inc.
  5. Other languages